AI Insight
Lipoprotein(a) is causally linked to increased risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Clinical trials with PCSK9 monoclonal antibody inhibitors demonstrate that elevated lipoprotein(a) levels increase both initial and recurrent cardiovascular events, while modest reductions of 20-25% in lipoprotein(a) concentrations result in substantial absolute reductions in cardiovascular risk. The article discusses advances in RNA interference therapeutics, specifically Kylo-11, for achieving deep and durable lowering of lipoprotein(a) levels.
Why it matters
This research highlights the potential of RNA interference therapeutics as a novel approach to significantly reduce lipoprotein(a) levels, which could provide more effective cardiovascular disease prevention than current treatments. The development of therapies targeting lipoprotein(a) may benefit millions of patients at high risk for cardiovascular events who do not respond adequately to existing lipid-lowering medications.
Understand the Science
Lipoprotein(a) is causally associated with an increased risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis.1 Clinical trials of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody inhibitors have shown that higher versus lower concentrations of lipoprotein(a) increase the risk of initial and recurrent cardiovascular events, and modest reductions in lipoprotein(a) concentrations of 20–25% are accompanied by larger absolute reductions in cardiovascular risk.
Source: [Comment] Deep and durable lipoprotein(a) lowering: Kylo-11 advances RNA interference therapeutics